Abstract
Introduction
The bile salt export pump (BSEP) is a liver resident transporter protein, which plays an essential role in the enterohepatic circulation of the bile salts [1, 2] . BSEP belongs to the ATP-Binding Cassette (ABC) protein family, the members of which are integral membrane proteins, defined by the existence of conserved sequences, the Walker A, Walker B, and the so called ABC signature motif. ABC transporters are composed of transmembrane domains (TMDs) containing typically 5-6 transmembrane helices (TMHs) and cytoplasmic ABC units or nucleotide binding domains (NBDs), which are responsible for the binding and hydrolysis of ATP, the energy of which is utilized for the translocations of transported substrates across the membrane. ABC proteins are present in all sorts of organisms; both uptake and efflux transporters (importers and exporters) can be found in prokaryotes, whereas ABC transporters in eukaryote plasma membrane are exclusively exporters.
The 48 human ABC proteins (classified into seven subfamilies, ranging from ABCA to ABCG) possess very different transport characteristics and contribute to diverse physiological functions, including detoxification, antigen presentation, and secretory processes. A group of ABC transporters, expressed in various physiological barriers and sanctuary sites of the body, form a complex network constituting an innate defense mechanism against endo-and xenobiotics, which is called the chemoimmunity system [3] . An important component of this defense system is the hepatic transport network, in which the bile salt export pump plays a pivotal role.
In this paper we give an overview on the current knowledge on the hepatic ABC transporter, BSEP. We discuss the model systems employed to understand its functional properties, the diseases associated with its malfunction, as well as the conventional and recently introduced therapies to cure these disorders. sequence and structural homology to the multidrug transporter P-glycoprotein (P-gp, MDR1, ABCB1), thus, BSEP was originally named sister of P-gp or Spgp [4] . Similar to Pglycoprotein, BSEP possesses a canonical ABC transporter membrane topology, having a domain order of TMD1-NBD1-TMD2-NBD2, as well as containing a large, heavily glycosylated extracellular loop in the first transmembrane domain, between TMH1 and TMH2. As a basic building principle of all other ABC transporters, organization of domains shows an internal dimeric arrangement; the two TMDs constitute a common structure in the membrane, as well as the two nucleotide binding pockets are composite sites jointly formed by the Walker A and Walker B motifs from one NBD with the ABC signature motif from the other NBD. It is generally accepted that intracellular coupling helices located between TMDs and NBDs convert the energy from ATP hydrolysis to conformational changes in the TMDs, thereby allowing substrate translocation. In BSEP the coupling helices have not been examined in detail, but their presence can be assumed on the basis of the high sequence homology to P-glycoprotein, in which these interacting helices have already been identified [5] .
In recent years, higher resolution crystal structures of several ABC exporters have become available. These include the bacterial SAV1866 [6] , the murine MDR1a/ABCB1 [7, 8] , and the human ABCB10 [9] transporters. Thus far the structure of BSEP has not been resolved, although homology models have been generated based on the crystal structures of SAV1866 and mouse MDR1a [10, 11] .
Unlike P-glycoprotein, which is present in a wide range of cell types, BSEP is selectively expressed in hepatocytes [4] . Although low levels of mRNA and protein expression were detected in the testis and adrenal gland of humans [12, 13] , the function of BSEP in these 6 tissues is unknown. BSEP is specifically expressed in the apical (canalicular) membrane of hepatocytes, but a substantial amount of BSEP can also be found in subapical vesicles [14, 15] . The apical surfaces of adjacent hepatocytes form a microscopic tube-like structure, the bile canaliculus, which is sealed by tight junctions (see Fig. 1 ). The bile canaliculi are interconnected, forming a complex tubular network, the smallest branches of the biliary tree of the liver. A detailed biochemical study demonstrated that under basal conditions only a small portion of BSEP resides in the canalicular membrane, the larger part is located in the intracellular vesicular pool, from which it can be rapidly mobilized to the cell surface [16] .
Following biosynthesis most canalicular membrane proteins, such as the transferrin receptor, are targeted from the Golgi apparatus to the basolateral surface first, then transcytosed to the canalicular membrane compartment. However, newly synthetized BSEP is delivered directly to the intracellular pool and then to the canalicular surface [16] . It has also been demonstrated that BSEP undergoes continuous cycling between the canalicular membrane and the rab11a-positive recycling endosomal pool [17] .
As most ABC transporters, BSEP is an active transporter powered by ATP binding and hydrolysis. Contrary to P-glycoprotein, which transports a wide variety of compounds, BSEP exports a restricted number of molecules, predominantly monovalent taurine-and glycineconjugated bile salts [18] . It has been proposed that unconjugated bile salts are also BSEP substrates; however, these molecules are probably transported only at very low rate (see in [19] ). Non-bile acid compounds, such as pravastatin and fexofenadine, have been reported to be transported by the human BSEP [20, 21] . In addition, it has been suggested that vinblastine and calcein-AM are substrates of the mouse BSEP (mBSEP) [22] . However, these results should be taken with caution, because these compounds are good MDR1 substrates, and MDR1 can easily be up-regulated in many cellular model systems. Although slight species differences in the substrate recognition of the human, rat, canine, and feline BSEP have been reported [23, 24] , the major transport function of this transporter seems to be evolutionary conserved [19] .
Physiological role and regulation of BSEP
A large fraction of bile constituents are continuously cycled in the enterohepatic circulation. About 95% of the bile salts travel through this cycle. A critical step in this process is the hepatic secretion of the bile, which is conducted by the transporters residing in the canalicular membrane of hepatocytes [2] . BSEP expels bile salts to the bile canaliculi, whereas MDR3/ABCB4 flips phosphatidyl choline (PC) to the outer leaflet of the membrane, resulting in net efflux of PC. The ABCG5/G8 heterodimer exports cholesterol to mixed micelles and PC vesicles. Other canalicular transporters including ATP8B1/FIC1, MRP2/ABCC2, MDR1/ABCB1, ABCG2, and the chloride-bicarbonate anion exchanger 2 (AE2) also contribute to the composition of bile by retaining aminophospholipids and exporting divalent bile salts, anionic conjugates, organic cations, glutathione, and bicarbonate to the bile (reviewed in [2, 25] ). It has been proposed that ABCG2 is capable of bile acid transport [26] , however, its physiological role, especially in the liver, is debated as discussed in detail in Ref. [2] . The basolateral (sinusoidal) transporters for bile acids include various solute carriers, such as NTCP, OATP1B1, OATP1B3, and OSTα/β [27, 28] ; export pumps, such as MRP3/ABCC3, MRP4/ABCC3 [29, 30] . NTCP and the OATPs responsible for the uptake of bile acids from the sinusoidal space into the hepatocytes, whereas MRP3, MRP4
and OSTα/β mediate a reverse transport, when it becomes necessary (see Fig. 1 ).
Export of bile salts driven by BSEP was shown to be the rate limiting step in bile secretion [1] . Thus, the expression and function of BSEP is a critical determinant of the enterohepatic circulation of the bile salts. The expression of BSEP is under the control of the farnesoid X receptor (FXR), a bile acid sensor, which forms heterodimer with RXRα upon activation, and consequently binds to FXR response element in the promoter of BSEP [31] .
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This FXR-mediated transcriptional activation can be further modified by other nuclear receptor co-activating proteins including ASCOM, CARM1, and SRC2 [32] . Moreover, FXRindependent transcriptional regulation of BSEP involves LRH1, NRF2, and PXR [32] .
In addition to the transcriptional control, the cell surface expression of BSEP can be rapidly modulated by mobilization of the intrahepatic, BSEP-containing vesicles, or inversely by controlling the internalization of the transporter from the canalicular membrane. This redistribution between the endosomal pool and the cell surface provides a fine-tuned regulatory mechanism, reacting promptly to the demand for the bile secretory capacity. The taurine-conjugated bile salt, taurocholate was shown to act not only as a bile constituent but also as a signaling molecule, which can trigger the delivery of BSEP to the canalicular membrane [16] . Recently, we have demonstrated that taurocholate-stimulated canalicular trafficking of BSEP is controlled by a signaling pathway that involves the EPAC/LKB1/AMPK kinase cascade [33] . In addition to taurocholate, cAMP also promotes BSEP trafficking to the canalicular surface by an alternative, PKA-dependent mechanism [16, 33] . PI3K has been shown to participate in the taurocholate-mediated redistribution of BSEP but not in the cAMP-stimulated response [34] . Another bile salt, tauroursodeoxycholate has been demonstrated to stimulate delivery of BSEP from the Golgi to the cell surface through the activation of p38 MAP kinase [35] . The presence and the half-life time of BSEP on the cell surface are determined not only by the delivery rate, but also by anchoring and internalization mechanisms. Numerous regulatory proteins such as cortactin, HAX-1, EPS15, AP-2, and IP3-receptor II have been suggested to participate in this process [36] .
Canalicular ABC transporters including MDR1, MRP2, ABCG5, and BSEP are localized in bile salt-resistant, cholesterol-and sphingomyelin-rich microdomains of the hepatocyte canalicular membrane [37, 38] . As previously shown for MDR1, MRP2, and ABCG2 [39] [40] [41] [42] , the activity of BSEP is modulated by the cholesterol content of the membrane [43, 44] . 
Human diseases associated with BSEP mutations
A large number of mutations and polymorphisms in the BSEP gene have been identified, which either cause hereditary liver diseases, or represent susceptibility factor for the development of various conditions affecting mainly the liver [11, 36, [49] [50] [51] [52] [53] . An up-to-date database summarizes the available information on the mutant variants of ABC transporters including BSEP (see http://abcmutations.hegelab.org/) [54] . All regions of BSEP can be affected, but the hot spots for mutations are the NBDs and the cytoplasmic loops. BSEP polymorphisms are ethnic dependent and usually rare, with the exception of the V444A and M677V variants, which exhibit allele frequencies ranging 50-93% and 0-15%, respectively, depending on the ethnic background [51] .
Hereditary liver diseases caused by loss of function mutations in BSEP include the progressive familial intrahepatic cholestasis type II (PFIC2) and the benign recurrent intrahepatic cholestasis type II (BRIC2). In these syndromes impaired bile salt secretion caused by the lack or insufficient amount of functioning BSEP in the canalicular membrane leads to intrahepatic cholestasis characterized by diminished bile production, reduced bile flow, and intrahepatic accumulation of toxic bile salts, concomitant with high plasma levels of bile salts and bilirubin. PFIC2 is an early onset disease with rapid progression frequently leading to end-stage liver complications before adulthood, whereas BRIC2 is characterized by recurrent episodes of cholestasis and consequent pruritus without substantial liver damage in most cases. PFIC2 patients are also susceptible to development of pediatric hepatocellular carcinoma (HCC) and cholangiocarcinoma [55, 56] . Several mutations in BSEP have been shown to be responsible for PFIC2 and/or BRIC2 (see Table 1 ). These include the relatively frequent E297G and D482G variants, which are present in 58% of European PFIC2 patients [49] .
The intrahepatic cholestasis of pregnancy (ICP) is a transient form of cholestatic liver diseases manifesting usually in the third trimester of pregnancy, and characterized by elevated serum bile acid levels, variable pruritus, fetal distress and increased risk for preterm delivery.
Numerous polymorphisms and mutations inBSEP, including the common V444A variant, have been identified as susceptibility factor for ICP [11, 51, [57] [58] [59] [60] [61] ; however, the mechanism how these variants contribute to the progression of ICP is unclear. High levels of estrogens and progesterone have been proposed to be responsible for the trans-inhibition of BSEP in the later stage of pregnancy [48] , but transcriptional repression of BSEP expression by 17β-estradiol and epiallopregnanolone sulfate has recently been demonstrated, providing an alternative model for the development of ICP [62] .
Substantial interindividual variability has been observed in the BSEP expression at both mRNA and protein levels even in healthy individuals [51, 63] . The frequent V444A variant was associated with low expression levels. Patients with BSEP-deficiencies usually exhibit reduced canalicular expression of BSEP. Staining with anti-BSEP antibodies of liver tissue samples combined with genotyping is a powerful method to evaluate the disorder [64, 65] .
Several studies reported recurrence of intrahepatic cholestasis due to the autoantibodies raised against BSEP after liver transplantation. The antibody originated from one of these cases recognizes an extracellular epitope of the human BSEP, moreover, suppresses its function [66] , providing an ideal tool for assessment of BSEP at the protein level. Inversely, the presence of autoimmune antibodies can be detected by canalicular antibody deposits in liver tissue samples subjected to the patients' serum, which specificity can be subsequently verified by Western blot analysis [11] .
Besides estrogens and progesterone metabolites, numerous drugs, including rifampicin, troglitazone, nefazodone, glibenclamide, cyclosporin A, and bosentan, have been shown to block BSEP function, thus, a cholestatic form of drug-induced liver injury (DILI) can develop upon treatment with these agents [53, [67] [68] [69] . The efforts to predict drug interaction with BSEP will be discussed later; nevertheless, the contribution of genetic factors to drug-induced cholestasis is also unambiguous. The frequent V444A variant and numerous rare mutations have been identified as risk factors for cholestatic DILI [52, 60, 61] . In addition to ICP and DILI, numerous BSEP variants are associated with several other liver diseases including primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), primary intrahepatic stones, gallstone disease, and neonatal cholestasis [70] [71] [72] . Despite the substantial amount of genomic data accumulated in the last decade, the etiological role of these BSEP mutations and SNPs in the acquired cholestatic liver diseases remains to be established.
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Although the association of BSEP mutations and polymorphisms with the above discussed liver diseases is clearly documented, the mechanisms how these mutations/SNPs lead to the syndromes are diverse and controversial. Mutations in the BSEP gene can result in defective bile salt secretion in several ways, which include reduced mRNA stability, protein misfolding and instability, loss of transport activity, as well as impaired trafficking to the canalicular surface. Nevertheless, a close correlation between the cell surface expression of BSEP and the clinical manifestation of PFIC2/BRIC2 has been demonstrated [73] . Even though the two most frequent disease-causing BSEP mutations (E297G and D482G) were extensively studied, the results are controversial. The discrepancies are likely stemmed from the differences in the applied experimental arrangements, including the different origin of BSEP in terms of species (human, rat, or mouse), and diversity of heterologous expression systems used for trafficking and/or transport studies. Table 1 summarizes the identified defects caused by various BSEP mutations and SNPs, specifying the major features of the used model systems.
Assessments of expression and function of BSEP
Reliable assay systems detecting BSEP expression, localization and function are crucial for dependable diagnosis and understanding the mechanisms of BSEP-related diseased conditions. The various detection methods assessing BSEP expression at the protein level with the help of anti-BSEP antibodies were discussed in the previous Section. Another approach to investigate the basis of reduced expression of BSEP is the so-called minigene system, which determines aberrations at the RNA level [50] . This method revealed abnormal pre-mRNA splicing in a considerable number of mutations and SNPs in the BSEP gene.
Different in vitro model systems are used to evaluate BSEP expression and function;
however, the results have to be interpreted carefully because of the complexity of bile salt circulation, drug metabolism, and transport systems. Some models aim at investigating certain 13 specific properties of the transporter, whereas others try to build a more complex net of transporters in a cellular context for measuring vectorial transport of bile salts. Variance in the applied cellular models may affect the intracellular fate of the studied BSEP variant. The robust Sf9 insect cell expression system commonly used for transport studies is relatively tolerant of protein misfolding, whereas mammalian cells, especially polarized epithelial cells are more sensitive to folding problems, thus, are also suitable for studying trafficking defects.
However, it should be noted that the trafficking machinery of the commonly used model cells, such as MDCK, HEK293, and HepG2, can considerably differ from that of the hepatocytes, the authentic cell type. This is exemplified by the fact that the stimulatory effect of taurocholate on BSEP trafficking can be observed in vivo and in isolated hepatocytes [16, 33] , but not in Wif-B9 liver model cells [17] .
Species differences add an extra complication, since dissimilarities between the properties of human and non-human BSEP may result in discrepancies in in vitro model systems. Common laboratory model animals, such as rats and mice, exhibit significant differences in bile composition, bile salt levels, and regulation as compared to humans. The ratio of glycine to taurine conjugates in humans is 3:1 and the prevalent form is chenodeoxycholate. The ratio is the reverse in rodents, and the bile composition is dominated by more hydrophilic bile salts [74] , making rodents less susceptible to cholestatic conditions.
Human and rodent BSEP expressed in heterologous systems exhibit different affinity for various bile salts. The highest affinity substrate of the human BSEP is taurocholate, whereas the preferred substrate of rodent BSEP is taurochenodeoxycholate [14, 18] . It should be noted that affinities for monovalent bile acid conjugates are very close, and the determined affinity orders vary to some extent with the experimental conditions (see more details in [19] ). Feline and canine BSEP proteins, sharing 91.2% homology with human BSEP, prefer taurineconjugated bile acid over glycocholic acid, and have lower affinity for unconjugated cholic 14 acid [24] . Although the affinities of BSEP for different substrates are slightly different, the substrate spectrum in general is fairly conserved [19] . Therefore, both human and rodent BSEP are used in in vitro assay systems to study transporter-drug interactions. Human BSEP is regularly employed in the vesicular transport measurements; whereas mouse or rat BSEP is preferred in the ATPase assay, since rodent versions of BSEP possess higher ATPase activities than the human counterpart [75] . Since the ATP activity of either BSEP variant is very low as compared to that of the multidrug transporters, the results obtained from these assays should be interpreted cautiously, because of the high risk for false positive and negative hits for inhibitors and stimulators, respectively.
Contrary to the human clinical experience, BSEP knockout mice have no marked liver disease only when challenged with high cholate diet [76] . These animals still secrete 30% of normal bile salts into bile, predominantly tauromuricholate and tetrahydroxylated bile salts, and exhibit elevated P-gp expression, which may help to prevent disease development [77, 78 ]. An interesting model option is mBSEP overexpression in the liver of mice [79] . These animals display enhanced biliary lipid (phospholipid and cholesterol) secretion paralleled with an increased bile salt output.
Vectorial transport of labelled bile salts, measured in rat or human sandwich-cultured hepatocytes represents a more complex model system. It should be noted that similar to the case of BSEP, other canalicular efflux and basolateral uptake transporters involved in the bile salt transport also show species differences [80, 81] . Modeling the differences in the transport and drug metabolic pathways between the human and animal hepatocytes may help to increase the reliability of animal-derived hepatocyte models in drug interaction tests.
The causes of drug-induced liver toxicity are diverse, and only a minor portion of DILI is 
In silico models for predictions of cholestatic effects of drugs
Various methods have been established to predict drug interactions with BSEP, as well as to evaluate mRNA and protein stability problems. ESE (exonic splicing enhancers) and ESS (exonic splicing silencer) prediction programs are used to identify nucleotide substitutions that could alter mRNA splicing [50] . Discrepancies in the experimental methods and the in silico predictions have made these estimations ambiguous thus far.
More sophisticated are the structure-based models for drug interactions, but no crystal structure is available for BSEP. Homology models for ABC exporters were generated on the basis of the few known crystal structures available, mainly that of the bacterial multidrug exporter, Sav1866 [6] . Recently, the mouse P-gp has been crystallized, and its structure has been resolved at a sufficiently good resolution. Since BSEP exhibits high sequence similarity to P-gp, its structure provides a better basis for homology modeling. It should be noted, however, that homology modeling always bears some uncertainties and especially the transmembrane regions in BSEP cannot be modeled reliably. Despite these problems, homology model was used to identify the extracellular epitope recognized by the anti-BSEP antibody mentioned above [66] .
Some drug interaction prediction methods are based on ligand characteristics, such as QSAR (structure activity model for ligands), pharmacophore models, and non-linear SPECS.
These methods are established and validated in high throughput BSEP in vitro drug interaction datasets, which were significantly expanded recently [10, 67, 68, 84, [87] [88] [89] [90] [91] .
A comprehensive, membrane vesicle-based study investigated a set of 624 compounds for BSEP inhibition [10] . Based on the physicochemical properties of the identified blockers, the inhibitory effect showed strong correlation with the lipophilicity and molecular size. It should, however, be noted that the IC 50 threshold for significant BSEP inhibition was set to 300 µM in this study, which may overestimate the number of blockers. Another study, using vesicular transport assay, identified 86 BSEP inhibitors out of 250 test compounds [87] .
QSAR modeling, here too, demonstrated a strong correlation between the lipophilicity and BSEP inhibition, whereas positive charge prevented the inhibitory effect. About 60% of the FDA-approved drugs, identified as BSEP inhibitors in this study, carry the risk for DILI according to the drug labels. Correlation between the severity of DILI and the inhibitory effect of the drugs on the taurocholate transport was also demonstrated using human hepatocyte sandwich cultures [87] .
Similarly, the frequency and severity of bile acid-mediated DILI in connection with BSEP inhibition are predicted by using DILIsym, a multi-scale mechanistic mathematical model (http://www.dilisym.com). A great amelioration is the incorporation of bile acid dynamics in the DILIsym [92] , thus, the model includes not only the metabolic pathways, mitochondrial toxicity, key transporters, etc., but also the synthesis, uptake, recirculation, efflux, and hepatotoxicity of bile acids. This complex approach may help to reduce discrepancies originated from species differences as well as from in vitro and in vivo experimental data, thereby allowing improved prediction of BSEP-related DILI [92] .
For its straightforwardness the pharmacophore modeling is commonly used for drug interaction prediction, however, the promiscuous drug binding site of ABC transporters also makes this approach challenging. Several models have been developed on congeneric series, which restricts their applicability to structurally related compounds [88] . A recent 3D
pharmacophore model aims at identifying functional groups common in BSEP-inhibiting molecules along with fixed intramolecular distances between interacting motifs [93] . This model is based on the inhibitory effect of test compounds with an IC 50 value of 50 µM or less, which was determined by human BSEP-containing membrane vesicles. The importance of hydrogen bond acceptors, anionic and loosely defined aromatic features were established as BSEP inhibitor pharmacophores, in which the exclusion volume has proven to be also important. This pharmacophore was subsequently confirmed with a set of 59 molecules.
Since latest surveys concluded that MRP4 inhibition has a significant impact in development of DILI, a new pharmacophore model has recently been developed that combines BSEP and MRP4 inhibitions [90] . Since MRP4 and BSEP have partially overlapping inhibitor profiles, modeling has to focus on both common and distinct features of these two sets of compounds. Welch et al. have built a Bayesian model, which has an increased predictive value as compared to other methods [91] . Their model underline the importance of high molecular weight, hydrophobicity, certain rotatable bonds and the aromatic features, which is in agreement with the conclusions of previous studies [87, 93] .
In summary, all the above discussed models and simulations have significant predictive potential, however, the complexity of bile acid metabolism and promiscuity of the potential drug binding site of BSEP create substantial uncertainties and require careful interpretation of predictions.
Pharmacological correction of BSEP deficiencies
Diseases associated with BSEP mutations and SNPs as well as the manifestation of these conditions are highly diverse, thus, therapeutic approaches also range from symptomatic treatment to major surgical interventions. The most severe form of BSEP deficiencies, PFIC2
is primarily treated surgically, which includes external or internal partial biliary diversion, ileal bypass, and even liver transplantation. Interestingly, the outcome of these surgical treatments to some extent depends on mutation type. For instance, the E297G and D482G mutations were associated with better prognosis after partial biliary external diversion [94] .
Similarly, nonsense and splice site mutations were more frequent in cases, when PFIC phenotype recurred after liver transplantation, due to the emergence of anti-BSEP antibodies [65] .
Numerous mutations and polymorphisms in the BSEP gene have been demonstrated to result in reduced mRNA level [50] . Transcriptional activation by nuclear receptor agonists, such as FXR ligands, provides a novel therapeutic approach to correct these deficiencies (reviewed in [32] ). In addition to FXR agonists, targeting of PXR, CAR, PPARα and PPARγ, The effect of ursodeoxycholic acids on the trafficking of BSEP is also controversial. Taurineconjugated UDCA promotes BSEP delivery to the canalicular surface [15, 35] , whereas UDCA have been shown to reduce BSEP internalization [96] . Nevertheless, the efficacy of the treatment was dependent on the BSEP mutation. A recent study demonstrated partial correction of impaired trafficking of BSEP with PFIC2-causing mutations by UDCA [97] .
Using chemical chaperones or correctors has recently become a rapidly developing field in the therapy of diseases associated with mutations in ABC transporter genes [98] .
Systematic screening revealed a series of small molecules that can rescue the impaired trafficking of misfolded CFTR-ΔF508, causing cystic fibrosis, the most frequent lethal inherited disease. Similar advances were achieved by in vitro and in vivo studies with ABCG2
and ABCC6 in connection with gout and pseudoxanthoma elasticum, respectively [99, 100] , although clinical studies have not yet performed in these diseases. The major corrector molecule used in these experiments is the 4-phenylbutyrate (4-PBA), an FDA-approved drug 21 for thalassemia and urea cycle disorders. This agent was found to increase cell surface expression of the BSEP mutants, D482G and E297G in vitro, as well as enhance bile salt excretion in vivo [73, 101] . Besides 4-PBA, bile salts were shown to act as pharmacological corrector stimulating the delivery of BSEP-E297G to the cell surface [102] . Even more exciting are the recent clinical data demonstrating that high-dose 4-PBA treatment can markedly improve the clinical parameters of PFIC2 patients bearing trafficking defect mutations in BSEP such as G982R, T1210P, R1128C, or R1231Q [97, 103, 104] . For many of these cases partial correction of canalicular expression of the mutated BSEP has also been demonstrated.
Expert opinion
The liver-resident membrane transporter protein, the bile salt export pump (BSEP) is a key component of the enterohepatic circulation. It controls the extrusion of monovalent bile salts into the bile canaliculi, the microscopic tubular structures formed by adjacent hepatocytes (see Fig. 1 ), which collect and direct bile to bile ducts. Since the export of bile salts is the rate limiting step in bile secretion [1] [97, 103, 104] . However, progress was achieved only with a very high dose of drug, and the reported improvements were sometimes transient.
In conclusion, further efforts should be made to improve the model systems to make them more reliable and better representing the human physiological and pathological conditions.
Evidently, there is a need for a change in our perception of BSEP-related disorders. We should integrate the experiences of the clinical studies, the vast information generated by contemporary molecular genetics, as well as the results of ex vivo, in vitro and in silico modeling. Only this integrative approach can make mutation-specific, personalized therapeutic interventions possible to cure BSEP-associated cholestatic liver diseases. Alternative routes for the canalicular bile salt export include MRP2 and supposedly ABCG2.
Annotations
The basolateral MRP3, MRP4, and OSTα/β transporters serve as an overflow system, mediating bile salt transport to the sinusoidal space, when needed. 
